Postdoc in the @ESontheimerLab at @RTI_UMassChan. PhD graduate from @NobregaFL lab.

Joined October 2021
Thomas Todeschini retweeted
I'm thrilled to share that I’ve officially launched my lab this week at the University of Pittsburgh Department of Ophthalmology/UPMC Vision Institute @Pitt_OPH ! I’m incredibly grateful for the mentorship and support I’ve received throughout my journey from @davidrliu , @ESontheimerLab , and Chonghui Cheng during my postdoctoral and graduate training. I’ve also been very fortunate to collaborate with outstanding scientists like Joe Hacia, Cat Lutz, Nancy Braverman, and Job Dekker, whose partnership has been truly invaluable. A heartfelt thank you to all my past colleagues and those I’ve met during the faculty interview process. The mission of the Gao Lab is to uncover fundamental biological mechanisms and translate these discoveries into transformative therapies that advance human health. We are hiring at all levels! If you're passionate about driving the future of genomic medicine, I’d love to hear from you. Learn more about my work: lnkd.in/eZpAgYD9 and please reach out to me via [email protected] More updates coming soon—stay tuned!
12
1
1
51
5,261
Thomas Todeschini retweeted
Data from the second human treated with a prime edited medicine: a 56-year-old male with chronic granulotamous disease (CGD) had his bone marrow prime edited to insert the missing GT in NCF1, restoring NADPH oxidase function in neutrophils (DHR positivity) several fold beyond the therapeutic threshold. His intestinal inflammation is now normal, and his prime-edited HSCs rapidly engrafted with 15 days post-transplant, consistent with well-tolerated editing. Each new therapeutic technology is dependent on brave patients willing to be among the first humans to receive a new type of treatment. For prime editing, that's this patient, and an 18-year old who also responded in a similarly encouraging manner. Patient #2 sent our lab a kind message, noting that helping other patients with rare diseases was deeply meaningful to him. Data from @PrimeMedicine.
17
136
23
625
61,289
Thomas Todeschini retweeted
Thrilled to see our Kiwa story out today! A membrane-associated supercomplex that senses infection and blocks replication and transcription. Huge congratulations to @ugobananas_uuu @Zhangzhiyi58692 and @TCTodeschini, and to all our collaborators. shorturl.at/l0ayB
3
36
85
5,599
Thomas Todeschini retweeted
It’s out! Read my review with @SorekLab on the nucleotide pool as a central playground in antiviral immunity across humans, bacteria and plants! 🧍‍♀️🦠🌿 & the diverse ways in which viruses overcome these nucleotide-based immune mechanisms 🗡️ nature.com/articles/s41577-0…
22
1
50
3,435
Thomas Todeschini retweeted
In @nature we describe the use of scalable #proteinengineering & #machinelearning to predict millions of bespoke CRISPR-Cas9 enzymes, offering safer & more genome editing tools. 🧬🖥️ @RachelSilvers11 @CGM_MGH @MGH_RI @MassGeneralNews @harvardmed nature.com/articles/s41586-0…
41
70
5
255
25,267
Excited to share my PhD work… and more CRISPR-Cas9 PAM variants than anybody asked for
In @nature we describe the use of scalable #proteinengineering & #machinelearning to predict millions of bespoke CRISPR-Cas9 enzymes, offering safer & more genome editing tools. 🧬🖥️ @RachelSilvers11 @CGM_MGH @MGH_RI @MassGeneralNews @harvardmed nature.com/articles/s41586-0…
1
9
57
3,407
Excited to share some recent PhD work together with @ruweyda97 and Anne van den Hurk, a review on Phage-Plasmids (P-Ps) and current knowledge. Fascinating MGEs that need more exploration! portlandpress.com/essaysbioc…
10
2
31
3,610
Exciting times! I will be giving a talk in session 3 about @KlebPhaCol make sure to tune in to learn more 👀
It's time! Klebsiella Seminar Series starts this week!🌟We are thrilled to announce the 2024 program and are excited to hear the latest Klebsiella research. #KlebClub🦠See you on Thursday! Registration is free and still live at: sites.google.com/view/klebcl…
2
1
12
2,763
Thomas Todeschini retweeted
Excited to see our work published in @Nature. Grateful to all the authors for their hard work, the reviewers for their insightful comments, friends for their help along the way.
Gabija is a prevalent defense system found in ~15% of sequenced bacteria. Elegant work led by @longfei_wang at @WHU_1893 unveils its activation mechanism against phage infection. Grateful to contribute to this study! nature.com/articles/s41586-0…
3
26
2,771
Thomas Todeschini retweeted
I’m really excited to share our new pre-print “Genome-wide Characterization of Diverse Bacteriophages Enabled by RNA-Binding CRISPRi”, with co-first author Muntathar Al-Shimary @doudna_lab and the newly-minted @bradyfcress lab! biorxiv.org/content/10.1101/… 🧵🧵 1/
13
70
6
188
49,244
Thomas Todeschini retweeted
Excited to see our story on defence system synergy now out in @cellhostmicrobe! 👇 sciencedirect.com/science/ar…
10
62
4
176
24,860
Thomas Todeschini retweeted
Clinical strains of Pseudomonas aeruginosa have accumulated phage defense systems in their genome matching their broad resistance to diverse phage families. Great work by Rita, Daan and Jelger. @AnaRitaMCosta, @DaanFvdBerg science.org/doi/10.1126/scia…
3
64
2
164
18,167
Thomas Todeschini retweeted
Just shared at @KeystoneSymp a new @ArcInstitute discovery of the bridge RNA recombinase mechanism: a new class of natural RNA-guided systems that retains the key property of programmability from RNAi and CRISPR while enabling large-scale genome design beyond RNA and DNA cuts
23
319
59
1,349
779,552
Thomas Todeschini retweeted
🔬Our preprint is out! "Genomic plasticity is a blueprint of diversity in Salmonella lineages". 🧬👩‍🔬 Thrilled to contribute to advancing our understanding of Salmonella pathogenesis. A huge thanks to my supervisors, @NobregaFL #Research #Salmonella 🌐 biorxiv.org/content/10.1101/…
5
16
1,231